secwatch.observer — SEC 8-K summary
======================================

Issuer:     EQRx, Inc. (—)
CIK:        0001843762
Form:       8-K
Filed at:   2023-05-08T23:59:59+00:00
Accession:  0001104659-23-057151
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 1.02, 2.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EQRx resets strategy, terminates two license deals, cuts 170 jobs, posts $82.6M Q1 loss
--------------------------------------------------------------------------------

- Terminates license agreements with CStone (sugemalimab/nofazinlimab) and Lynk (EQ121 JAK-1 inhibitor); partners regain rights outside Greater China.
- Approves restructuring: ~170 positions eliminated; estimated total restructuring costs $45M-$55M in 2023; expects annualized cash savings of at least $125M.
- Q1 2023 net loss $82.6M vs net income $20.7M in Q1 2022; cash and investments $1.3B; expects year-end cash ~$1.1B.
- Prioritizing lerociclib (CDK4/6 inhibitor) with Phase 3 trial in endometrial cancer; seeking partnerships for aumolertinib outside Greater China.
- Plans to separate early-stage immune-inflammatory programs into new subsidiary and explore its path as an independent company.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1843762/000110465923057151/0001104659-23-057151-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1843762/000110465923057151/tm2314964d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-057151

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer